A specialist of infectious diseases in America Dr. Anthony Fauci on Thursday said his country really wanted to involve Indian researchers in global clinical trials to evaluate the safety and efficacy of Covid-19 therapy.
The National Allergy Institute and Infectious Diseases have a long history of collaboration with partner agencies in India, Dr. Fauci said during a conversation organized by the US-India Strategic Forum and Partnership.
“Under a long-standing Indo-US vaccine action program, we will continue to work with India in research related to the SARS-COV-2 vaccine (severe acute respiratory syndrome Coronavirus 2). We also want to involve Indian researchers on the site in Indonesia Global clinical trials to evaluate the safety and efficacy of various Covid-19 therapies, “he said.
The partnership between the biotechnology department and India and what the Indian Medical Research Council has helped produce important scientific and public health findings in the past.
“I am sure they will continue to do it in the future. India’s contribution to global scientific knowledge is also known by all. With the support of a strong government and a vibrant private biofarma sector, this knowledge has resulted in a solution for Covid-19 prevention and treatment” said Dr. Fauci ,
The Indian Ambassador to the US Tararjit Singh Sandhu said when India increased vaccine production to meet their needs and the world that depend on the support of the United States in ensuring raw materials and component items available in good inventory.
“World vaccination is our best bet of other pandemic waves, and the ideal way to accelerate economic recovery,” he said.
Observing that Indian-US health collaboration was not new, he said under the old vaccine program between the two countries, they developed a vaccine against Rotavirus, which caused severe diarrhea to children.
Indian companies have also produced, HIV drugs that are very cost-effective for use in African countries, build cooperation between US organizations and the private sector, he said.
“In the future, we need to invest in preparing the future. Global resistance in the future will depend on how ready we are in dealing with future pandemics. We need to work to expand our bilateral program in fields such as epidemiology, digital health and Patient security to deal with infectious diseases, and not contagious and increase modeling of infectious diseases, predictions and forecasting.
Similarly, the distribution of clinical, standard, and hospital experiences, in managing infectious diseases, especially Covid-19, will increase the knowledge base, “Sandhu said.
“I think it’s important to understand when the US passes through the crisis last year, it is India which continues to support the US from critical medicine. And India will go through its own challenges, we go up. So, it is a reciprocal partnership.,” Said President of Usispf Mukesh Aghai.
Sandhu said last year, when a hit pandemic, India ensured the integrity of health supply chains, providing important drugs for the US.
“This year, when the US supports India during the second wave, President Biden remembers Indian assistance. Companies such as Gilead and Merck are present here today has been critical in supplying essential drugs to India that have helped us fight pandemics and save countless lives In number, “he said.
